Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Cases
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 iota-carrageenan studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Cases   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 80% 1 394 Improvement, Studies, Patients Relative Risk Cases 80% 1 394 RCTs 80% 1 394 Prophylaxis 80% 1 394 Iota-carrageenan for COVID-19 c19ic.com May 2022 Favorsiota-carrageenan Favorscontrol
0 0.5 1 1.5+ ALL STUDIES CASES RCTS All Prophylaxis Iota-carrageenan for COVID-19 C19IC.COM MAY 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 study c19ic.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 case result c19ic.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 Randomized Controlled Trials c19ic.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 peer reviewed trials c19ic.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control iota-carrageenan COVID-19 outcomes c19ic.com May 2022 Favors iota-carrageenan Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0